Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M. El Sahly, Jacqueline M. Miller, Lisa A. Jackson et al.|New England Journal of Medicine|2021Cited by 661
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialSpyros Chalkias, Rituparna Das, Frank Eder et al.|Nature Medicine|2022Cited by 144
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSpyros Chalkias, Rituparna Das, Jordan L. Whatley et al.|Nature Medicine|2023Cited by 77
Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSpyros Chalkias, Rituparna Das, Frank Eder et al.|Research Square|2022Cited by 24